Dark

Check out our Level2View

COCP
Cocrystal Pharma, Inc. Common Stock
stock NASDAQ

At Close

Aug 29, 2025 3:59:30 PM EDT

1.50USD-4.459%(-0.07)44,970

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-1.57)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

12:22PM EST Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19 Benzinga

08:09AM EST Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates For Its COVID-19 Oral Drug Program Benzinga

08:00AM EST Novel broad-spectrumoral lead candidates CDI-988 and CDI-873,discovered using Cocrystals antiviral drug discovery platform,demonstratesuperiorin vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron GlobeNewswire Inc

Jan 6, 2022

08:03AM EST Cocrystal Pharma Reports FDA Guidance To Advance Clinical Development Of Its COVID-19 Antiviral Benzinga

08:00AM EST Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 GlobeNewswire Inc

Jan 4, 2022

08:00AM EST Cocrystal Pharma to Present at the H.C. Wainwright BioConnect GlobeNewswire Inc

Dec 22, 2021

08:05AM EST Cocrystal Pharma Announces In Vitro Studies Showing COVID-19 Oral And Intranasal/Pulmonary Protease Inhibitors Exhibit Antiviral Activity Against SARS-CoV-2, Including Omicron, Delta, Alpha, Beta And Gamma Variants Benzinga

08:00AM EST Antiviral activity now confirmed against SARS-CoV-2 and all variants of concernincluding Omicron, Delta, Alpha, Beta and Gamma GlobeNewswire Inc

Dec 2, 2021

08:10AM EST Cocrystal Pharma To Discuss Progress With COVID-19 Antiviral Programs And Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow Dec. 8 Benzinga

08:00AM EST Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral GlobeNewswire Inc

Dec 1, 2021

04:09PM EST Cocrystal Pharma Highlights Presentation Of Preclinical Data From COVID-19 Antiviral Programs, Outlines Near-Term Clinical Plans At World Antiviral Congress Benzinga

04:05PM EST Unveils designs for Phase 1 and 2 studies withintranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiationsexpected in 2022 GlobeNewswire Inc

Nov 15, 2021

11:02AM EST Cocrystal Pharma Q3 EPS $(0.04) Up From $(0.05) YoY Benzinga

08:00AM EST Cocrystal Pharma Reports Third Quarter Financial Results and GlobeNewswire Inc

Nov 8, 2021

08:21AM EST Cocrystal Pharma Says Its Main Protease Inhibitors Demonstrated Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses And Enteroviruses Benzinga

08:00AM EST Cocrystal Pharmas SARS-CoV-2 Main Protease GlobeNewswire Inc

Nov 1, 2021

08:01AM EDT Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package To The FDA For Clinical Development Guidance Of CDI-45205 For COVID-19 Treatment Benzinga

08:00AM EDT FDAs response is expected to provide greater clarity and guidance on designingPhase 1 and Phase 2 clinical trials for CDI-45205 GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT Cocrystal Pharma To Present Data From Oral And Intranasal COVID-19 Therapeutics Programs At The World Antiviral Congress 2021 Benzinga

08:00AM EDT Cocrystal Pharma to Present Data from its Oral and Intranasal GlobeNewswire Inc

Oct 14, 2021

08:10AM EDT Cocrystal Pharma To Present At The Dawson James 2021 Small Cap Growth Conference On October 21, 2021 Benzinga

08:00AM EDT Cocrystal Pharma to Present at the Dawson James 2021 Small Cap GlobeNewswire Inc

Oct 6, 2021

08:49AM EDT Cocrystal Pharma Receives Australian Regulatory Clearance To Initiate Phase 1 Study Of CC-42344 For Treatment Of Pandemic And Seasonal Influenza Benzinga

08:49AM EDT Cocrystal Pharma Receives Australian Regulatory Clearance to GlobeNewswire Inc

Sep 7, 2021

08:00AM EDT Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 16, 2021

08:23AM EDT Cocrystal Pharma Q2 EPS $(0.04) Up From $(0.07) YoY Benzinga

08:00AM EDT Cocrystal Pharma Reports Second Quarter 2021 Financial Results and GlobeNewswire Inc

Jul 29, 2021

08:07AM EDT Cocrystal Pharma Announces Its SARS-CoV-2 3CL Protease Lead CDI-45205 Showed In Vitro Activity Against Delta And Gamma Variants Benzinga

08:00AM EDT Cocrystal Pharmas SARS-CoV-2 3CL Protease Lead GlobeNewswire Inc

Jun 28, 2021

08:00AM EDT Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021. GlobeNewswire Inc

Jun 23, 2021

08:00AM EDT Cocrystal Pharma Completes IND-Enabling Studies With CC-42344 For Treatment Of Seasonal And Pandemic Influenza A, Plans To initiate Phase 1 Trial In Q3 Benzinga

08:00AM EDT Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for GlobeNewswire Inc

Jun 14, 2021

09:48AM EDT Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains Benzinga

09:14AM EDT Biotechnology company Cocrystal Pharma Inc. (COCP) announced Monday that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. RTTNews

08:39AM EDT Cocrystal's CDI-45205 Is Active Against SARS-CoV-2 And Two Prominent SARS-CoV-2 Variants RTTNews

08:31AM EDT Cocrystal's Says Lead COVID-19 Antiviral CDI-45205 Shown To Be Active Against SARS-CoV-2 And 2 Prominent SARS-CoV-2 Variants Benzinga

08:30AM EDT Cocrystals Lead COVID-19 Antiviral CDI-45205 GlobeNewswire Inc

Jun 9, 2021

02:30PM EDT Cocrystal Pharmas Participation in the Noble GlobeNewswire Inc

Jun 3, 2021

03:05PM EDT Cocrystal Pharma Files For U.S. Patent Titled 'COMBINATION THERAPY FOR TREATMENT OF HCV' Benzinga

May 28, 2021

08:01AM EDT Cocrystal Pharma Announces Passing Of Chairman, CEO And Co-founder Dr. Gary Wilcox Benzinga

08:00AM EDT Cocrystal Pharma Announces the Passing of Chairman, CEO and GlobeNewswire Inc

May 17, 2021

10:24AM EDT Cocrystal Pharma shares were trading higher after the company reported Q1 EPS results up from last year. Benzinga

08:07AM EDT Cocrystal Pharma Q1 EPS $(0.04) Up From $(0.05) YoY Benzinga

08:00AM EDT Cocrystal Pharma Reports First Quarter 2021 Financial Results and GlobeNewswire Inc

May 7, 2021

04:05PM EDT Cocrystal Pharma Announces Closing of $40 Million Bought Deal GlobeNewswire Inc

May 5, 2021

02:52PM EDT Mid-Afternoon Market Update: Dow Surges 180 Points; Big 5 Sporting Goods Shares Spike Higher Benzinga

12:17PM EDT Mid-Day Market Update: Crude Oil Rises 1%; Esperion Therapeutics Shares Drop Following Q1 Results Benzinga

10:26AM EDT Mid-Morning Market Update: Markets Mostly Lower; General Motors Profit Beats Estimates Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

06:38AM EDT Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount Benzinga

May 3, 2021

01:14PM EDT Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate Benzinga

08:06AM EDT Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs Benzinga

08:00AM EDT Cocrystal Pharma Provides Update on its COVID-19 Antiviral GlobeNewswire Inc

Apr 29, 2021

01:28PM EDT Cocrystal Pharma Files For U.S. Patent Titled 'PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION' Benzinga

Apr 8, 2021

03:25PM EDT Cocrystal Pharma Australian Patent Office Abstract Titled 'Inhibitors of hepatitis C virus polymerase' Benzinga

Mar 17, 2021

08:48AM EDT Cocrystal Pharma Q4 EPS $(0.01), Sales $510.00K Benzinga

08:30AM EDT Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs GlobeNewswire Inc

Mar 10, 2021

08:12AM EST Cocrystal Pharma Extends Drug Discovery Collaboration With HitGen And InterX Through August 2023; Financial Details Not Disclosed Benzinga

08:00AM EST Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen GlobeNewswire Inc

Mar 9, 2021

07:00AM EST Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth GlobeNewswire Inc

Mar 2, 2021

11:28AM EST Cocrystal Pharma to Present at the H.C. Wainwright Global Life GlobeNewswire Inc

Jan 21, 2021

08:00AM EST Cocrystal Pharma Presentation at the reimagine Health Research GlobeNewswire Inc

Jan 19, 2021

08:02AM EST Cocrystal Pharma Reports Completed All Research Obligations Under Merck Exclusive Global License, Collab Deal; Merck Is Solely Responsible For Further Development Of Influenza A/B Antiviral Compounds Benzinga

08:00AM EST Cocrystal Pharma Announces Further Development of Influenza A/B GlobeNewswire Inc

Jan 14, 2021

08:00AM EST Cocrystal to Present at the 3rd Annual reimagine Health Research GlobeNewswire Inc

Jan 12, 2021

08:00AM EST Cocrystal Pharma, Inc. (Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Capital Markets 17th Annual Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time). GlobeNewswire Inc

Jan 5, 2021

08:00AM EST Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect GlobeNewswire Inc

Dec 22, 2020

08:49AM EST Cocrystal Pharma Selects Lead Compound CDI-45205 For Further Development Against Coronaviruses RTTNews

08:34AM EST Cocrystal Pharma Selects Lead Compound For Further Development Against Coronavirus Benzinga

08:30AM EST CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 GlobeNewswire Inc

Dec 18, 2020

04:43PM EST Cocrystal Pharma Announces That On Dec 10 The Co. Received A Letter From Nasdaq Notifying Co That It Had Regained Compliance With Minimum Bid Price Requirement Benzinga

Nov 16, 2020

08:15AM EST Cocrystal Pharma Q3 Sales $489K, Reports $31.781M Cash On Hand As Of Sept. 30 Benzinga

08:05AM EST Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end GlobeNewswire Inc

Nov 12, 2020

06:30AM EST HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $4.5 Benzinga

Nov 10, 2020

01:19PM EST Cocrystal Shares Quiet Following Several Recent Tweets From Co. '$COCP Selected to Present at the World Antiviral Conference,' '...will discuss COCP novel, broad spectrum flu antivirals, novel antiviral compounds for the treatment of coronavirus' Benzinga

08:05AM EST Cocrystal Pharma Selected to Present at the World Antiviral Conference GlobeNewswire Inc

Nov 6, 2020

08:00AM EST Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST GlobeNewswire Inc

Oct 19, 2020

08:05AM EDT New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain GlobeNewswire Inc

Oct 2, 2020

08:05AM EDT Cocrystal Pharma, Inc.(NASDAQ:COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, District of New Jersey, regarding Agreement of Settlement. GlobeNewswire Inc

Sep 8, 2020

08:00AM EDT Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT GlobeNewswire Inc

Sep 7, 2020

08:00AM EDT The Rosen Law Firm, P.A. announces that the United States District Court for the District of New Jersey has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Cocrystal Pharma, Inc. and/or BioZone Pharmaceuticals, Inc. (NASDAQ: COCP): GlobeNewswire Inc

Aug 31, 2020

12:05PM EDT Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal GlobeNewswire Inc

Aug 27, 2020

02:30PM EDT Mid-Afternoon Market Update: Dow Surges 250 Points; VBI Vaccines Shares Climb Benzinga

12:21PM EDT Mid-Day Market Update: Nasdaq Turns Positive; BMC Stock Holdings Shares Spike Higher Benzinga

Aug 26, 2020

10:00PM EDT Cocrystal Pharma Increases Previously Announced Bought Deal to $15 GlobeNewswire Inc

05:36PM EDT Cocrystal Pharma Announces $10.0 Million Bought Deal Offering GlobeNewswire Inc

Aug 7, 2020

09:46AM EDT UPDATE: Cocrystal Shares Had Spiked Higher On Aug. 3 Following Trader Circulation Of An American Association For Advancement Of Science-Published Report From Kansas State Unversity Virologists On Potential Coronavirus Treatment Benzinga

Aug 4, 2020

06:52PM EDT Cocrystal Pharma Releases Investor Presentation Benzinga

08:13AM EDT Cocrystal Pharma Highlights Publication By Collaborators Of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus In Science Translational Medicine Journal Benzinga

08:05AM EDT Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication GlobeNewswire Inc

Share